Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis
Open Access
- 17 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
Abstract
Background: Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumor. Carmustine is used by intravenous injection or local implantation in the resection cavity for gliomas, including GBMs. However, the therapeutic potential of carmustine is not well-recognized. This analysis aimed to evaluate the survival benefits of carmustine in glioma patients, especially those with GBM. Methods: Randomized controlled trials (RCTs) and cohort studies regarding carmustine for glioma treatment were searched in PubMed, the Cochrane Library, and Embase from January 1979 to March 2020. Quality assessment was conducted with Jadad and Newcastle–Ottawa scales (NOS). Statistical analysis was conducted by the Revman 5.3 software. Results: Twenty-two eligible RCTs and cohort studies involving 5,821 glioma patients were included. Overall, glioma patients receiving carmustine as an adjuvant therapy had better progression-free survival [PFS; hazard ratio (HR) = 0.85, 95% CI = 0.77–0.94, P = 0.002] and overall survival (OS; HR = 0.85, 95% CI = 0.79–0.92, P < 0.0001) than those without carmustine treatment. Subgroup analysis showed that the OS benefit was observed in GBM (HR = 0.84, 95% CI = 0.78–0.91, P < 0.00001) but not in anaplastic glioma patients (HR = 1.20, 95% CI = 0.70–2.07, P = 0.50). Additionally, both newly diagnosed and recurrent GBM patients who received carmustine treatment showed better OS (HR = 0.86, 95% CI = 0.79–0.95, P = 0.002; HR = 0.77, 95% CI = 0.67–0.89, P = 0.0002, respectively). Both carmustine implantation in resection cavity and intravenous administration significantly prolonged OS (HR = 0.84, 95% CI = 0.78–0.92, P < 0.0001; HR = 0.86, 95% CI = 0.75–0.99, P = 0.04, respectively). Moreover, GBM patients receiving a combined carmustine and temozolomide (TMZ) therapy had longer OS than those receiving TMZ alone (HR = 0.78, 95% CI = 0.63–0.97, P = 0.03). Conclusion: Carmustine implantation in resection cavity provides survival benefit for GBM patients, and it may be a promising supplement to standard therapeutic protocol by offering a bridge between surgical resection and onset of TMZ therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81573459)
This publication has 45 references indexed in Scilit:
- Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect ComparisonPLoS Neglected Tropical Diseases, 2013
- Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomaActa Neurochirurgica, 2012
- NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practiceBritish Journal of Neurosurgery, 2012
- A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiformeJournal of Neurosurgery, 2010
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaNeuro-Oncology, 2010
- Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapyCancer, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986